AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...
AstraZeneca still trades at a premium valuation, but several factors limit its upside potential in the next visible period. There are three negative takeaways from China. IRA could also ...
An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...
FDA approves AstraZeneca's Datroway, reducing breast cancer progression risk by 37% per TROPION-Breast01 trial results. Datroway's safety profile remains consistent, with 4.2% ILD rate ...
Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's (4568.T), opens new tab precision drug to treat a type of ...
A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...
A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...
Jan 17 (Reuters) - AstraZeneca (AZN.L), opens new tab has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times ...
AstraZeneca PLC AZN-Q is investing $820-million and creating more than 700 jobs in Ontario’s life sciences industry, stimulating growth within a national research and development sector that has ...
AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...
When we think of artificial intelligence (AI), data science and the potential real-world impact of these rapidly developing fields, we tend to look to the future—particularly when it comes to ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback